Cigna earnings beat by $0.04, revenue topped estimates
Investing.com -- KKR, a global investment firm, has withdrawn from a private equity consortium considering a takeover of Gerresheimer AG (BS:GXId), a German company known for producing pens used to inject weight-loss drugs like Novo Nordisk (NYSE:NVO)’s Wegovy. This information was reported by Bloomberg on Thursday.
Warburg Pincus, another global private equity firm that was part of the same consortium, is continuing its efforts to reach a deal. Earlier this month, it was reported that the consortium, which included both KKR and Warburg Pincus, had put forth a non-binding bid for Gerresheimer.
Gerresheimer had received a bid from the consortium at about 90 euros per share. This offer would have valued the company at nearly 3.1 billion euros, equivalent to $3.42 billion.
As of now, neither KKR nor Gerresheimer have responded to requests for comments on the matter. Warburg Pincus, on the other hand, has declined to comment.
Earlier this year in February, Gerresheimer had announced that it was in the preliminary stages of discussions with private equity investors regarding a potential sale of the company. The company had clarified at the time that the expressed interest was informal and on a non-binding basis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.